The first vaccination campaign for pregnant women by Abrysvo, with a view to protecting bronchiolitis newborns in VRS, was held from September 15, 2024 to January 31, 2025. In total, 27.2 % of targeted pregnant women were vaccinated, according to a study that has just been published.
The first vaccination campaign for pregnant women between 32 and 36 weeks of amenorrhea (SA) by the Abrysvo vaccine to protect newborns from bronchiolitis to VRS was held from September 15, 2024 to January 31, 2025. In total, 27.2 % of eligible pregnant women were vaccinated by Abrysvo (72,026 pregnant women on 264,471) EPI-Phare (ANSM/CNAM) which based on the National Health Data System (SNDS). “The vaccination rate was maximum, by 45 %, in women who started a pregnancy in May 2024 and whose 8th month of pregnancy (December 2024) coincided with the period when the circulation of the VRS was the highest”specifies the study.
However, there are strong socio-demographic and territorial disparities. It is thus observed that, compared to women who have not received Abrysvo, “Those vaccinated were older (median of 31.5 years vs 30.6 years), resided more frequently in a socially favored commune or a municipality with better potential access to the general practitioner (36.4 % vs 31.7 %), and were less frequently beneficiaries of the Complementary solidarity health (12,6 % vs 25,3 %) ». As for the prevalence of comorbidities, it was generally similar between vaccinated and not vaccinated women.
The vaccination rate varies a lot according to the department, ranging from 8.7 % in the Alpes-de-Haute-Provence to 46.4 % in Finistère. In addition, women vaccinated by Abrysvo have better respected the other recommended vaccinations in pregnant women: during this same pregnancy, 96.1 % of them were delivered a painting against pertussis (against 65.5 % in non-vaccinated) 37.2 % a vaccine against flu (against 5.4 %) and 11.1 % a vaccine against COVV-19 among non-vacuums).
Recall that the prevention of infant bronchiolitis is possible via Mother’s vaccination by Abrysvo, but also by immunization of the newborn with Beyfortus (Nirsévimab). “In order to overall estimate the protection of infants against severe infections due to the VRS during the 2024-2025 season, abrysvo vaccination data will have to be supplemented by beyfortus’ deliveries”indicate the authors. In addition, it will be important to follow, in the next campaigns, the evolution of the proportion of immune children via Beyfortus and mothers vaccinated by Abrysvo. “Indeed, many studies abroad show that women would prefer to be vaccinated during pregnancy rather than immunizing children at birth”evoke the authors.
